Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Why are myelodysplastic syndromes unrecognized and underdiagnosed? A primary care perspective.

Khan AM.

Am J Med. 2012 Jul;125(7 Suppl):S15-7. doi: 10.1016/j.amjmed.2012.04.017.

PMID:
22735746
2.

Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes.

Foran JM, Shammo JM.

Am J Med. 2012 Jul;125(7 Suppl):S6-13. doi: 10.1016/j.amjmed.2012.04.015. Review.

PMID:
22735753
4.

Myelodysplastic syndromes: a practical approach to diagnosis and treatment.

Barzi A, Sekeres MA.

Cleve Clin J Med. 2010 Jan;77(1):37-44. doi: 10.3949/ccjm.77a.09069. Review.

5.

The myelodysplastic syndromes.

Nguyen PL.

Hematol Oncol Clin North Am. 2009 Aug;23(4):675-91. doi: 10.1016/j.hoc.2009.04.008. Review.

PMID:
19577164
6.

Myelodysplastic syndromes.

Utley SM.

Semin Oncol Nurs. 1996 Feb;12(1):51-8. Review.

PMID:
8650442
7.

Myelodysplastic syndromes: the pediatric point of view.

Locatelli F, Zecca M, Pession A, Maserati E, De Stefano P, Severi F.

Haematologica. 1995 May-Jun;80(3):268-79. Review.

8.

Important features of myelodysplastic syndrome.

Hofmann WK, Koeffler HP.

Int J Hematol. 2002 Aug;76 Suppl 2:222-7. Review.

PMID:
12430929
9.

Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis.

Imbert M, Nguyen D, Sultan C.

Leuk Res. 1992;16(1):51-4. Review.

PMID:
1732672
10.

Issues in the pathology of the myelodysplastic syndromes.

Kampmeier P, Anastasi J, Vardiman JW.

Hematol Oncol Clin North Am. 1992 Jun;6(3):501-22. Review.

PMID:
1613003
11.

Experience in pediatric myelodysplastic syndromes.

Gadner H, Haas OA.

Hematol Oncol Clin North Am. 1992 Jun;6(3):655-72. Review.

PMID:
1613011
12.

[Intense neutropenia of 14 years duration as the only manifestation of a myelodysplastic syndrome].

Las Heras G, Marti JM, Villamor N, Ribera JM, Feliu E, Rozman C.

Med Clin (Barc). 1995 Nov 11;105(16):619-21. Review. Spanish.

PMID:
8523943
13.

Myelodysplastic syndromes in the adolescent.

Winter SS, Mathew P, Vaughan RL, Foucar K.

Adolesc Med. 1999 Oct;10(3):401-6, x. Review.

PMID:
10611937
14.

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK.

Ann Hematol. 2010 Sep;89(9):841-50. doi: 10.1007/s00277-010-1015-0. Epub 2010 Jun 22. Review.

PMID:
20567826
15.

Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.

Jabbour E, Kantarjian HM, Koller C, Taher A.

Cancer. 2008 Mar 1;112(5):1089-95. doi: 10.1002/cncr.23280. Review.

16.
17.

A comparative review of classification systems in myelodysplastic syndromes (MDS).

Bennett JM.

Semin Oncol. 2005 Aug;32(4 Suppl 5):S3-10. Review.

PMID:
16085011
18.

Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.

Gore SD, Hermes-DeSantis ER.

Cancer Control. 2009 Oct;16 Suppl:2-10. Review.

19.

Treatment strategies in myelodysplastic syndromes.

Atallah E, Garcia-Manero G.

Cancer Invest. 2008 Mar;26(2):208-16. doi: 10.1080/07357900701788122. Review.

PMID:
18259954
20.

Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions.

Valent P, Horny HP.

Eur J Clin Invest. 2009 Jul;39(7):548-53. doi: 10.1111/j.1365-2362.2009.02151.x. Epub 2009 May 6. Review.

PMID:
19453651

Supplemental Content

Support Center